See What HealthDay Can Do For You
Contact Us

Majority of Drugs Tolerated After Negative Re-Challenge

90 percent of re-challenged drugs subsequently tolerated by patients with adverse reactions

MONDAY, March 14 (HealthDay News) -- Patients who suffer from cutaneous adverse drug reactions (CADR) and have a negative re-challenge under hospital surveillance (RCH) show good tolerance when re-challenged with the same drug, according to a study published online Feb. 9 in Allergy.

J. Waton, from the University Hospital of Nancy in France, and colleagues investigated whether 349 patients with 637 negative drug RCH could tolerate treatment with the same drugs at a later point. Patients who had experienced a negative RCH in the last 10 years were interviewed by the same researcher to assess if they were later able to tolerate the drug and why drugs might not have been taken again.

The researchers identified a group of 134 drugs that were taken again. In this group, there were 12 adverse reactions in 10 patients. In a second group, 359 drugs were not taken again because 76 percent of the patients evaluated for drug or radiocontrast media intolerance either did not need another course of these products or because their physician did not want to prescribe the drugs.

"Patients and physicians need adequate documentation regarding drugs that must be avoided and those that are well tolerated. In addition, patients and physicians require education to permit the subsequent re-intake of drugs, which were well tolerated in almost 91 percent of cases with a history of CADR, and who without these immuno-allergic investigations would possibly not take many classes of drugs, useful for them," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.